[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mink Therapeutics Inc (INKT)

Mink Therapeutics Inc (INKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,146
  • Shares Outstanding, K 4,982
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,490 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.63
  • Number of Estimates 1
  • High Estimate $-0.63
  • Low Estimate $-0.63
  • Prior Year $-0.65
  • Growth Rate Est. (year over year) +3.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.21 +10.38%
on 07/22/26
11.97 -5.85%
on 08/06/26
-0.14 (-1.23%)
since 07/14/26
3-Month
9.47 +19.05%
on 05/18/26
13.40 -15.90%
on 06/04/26
+0.76 (+7.23%)
since 05/14/26
52-Week
8.48 +32.90%
on 03/24/26
18.17 -37.97%
on 08/15/25
-4.05 (-26.44%)
since 08/14/25

Most Recent Stories

More News
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support...

INKT : 11.27 (+2.45%)
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor support Analysis of blood and...

INKT : 11.27 (+2.45%)
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...

INKT : 11.27 (+2.45%)
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Previously announced oversubscribed $85 million private placement, with up to an additional $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution ...

AGEN : 7.32 (+4.57%)
INKT : 11.27 (+2.45%)
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)...

INKT : 11.27 (+2.45%)
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria Landmark advances a first-in-class...

INKT : 11.27 (+2.45%)
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Noetik’s TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival ...

AGEN : 7.32 (+4.57%)
INKT : 11.27 (+2.45%)
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features In the overall BOT+BAL...

AGEN : 7.32 (+4.57%)
INKT : 11.27 (+2.45%)
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15...

INKT : 11.27 (+2.45%)
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall survival of 12.3 months in a heavily pretreated...

AGEN : 7.32 (+4.57%)
INKT : 11.27 (+2.45%)

Business Summary

MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York....

See More

Key Turning Points

3rd Resistance Point 12.08
2nd Resistance Point 11.79
1st Resistance Point 11.53
Last Price 11.27
1st Support Level 10.98
2nd Support Level 10.69
3rd Support Level 10.43

See More

52-Week High 18.17
Fibonacci 61.8% 14.47
Fibonacci 50% 13.32
Fibonacci 38.2% 12.18
Last Price 11.27
52-Week Low 8.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.